• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

July 11, 2014

View Archived Issues

Regeneron, Sanofi showcase positive phase IIb data on dupilumab

Regeneron Pharmaceuticals Inc. and partner Sanofi SA will launch pivotal studies of the potential blockbuster allergy therapeutic dupilumab (REGN668/SAR231893) by the end of this year on the heels of encouraging phase IIb data showing it helped clear skin lesions in patients with a serious, chronic and hereditary form of eczema called atopic dermatitis (AD). Read More

EMA fails to finalize data access policy

Board disagreements have delayed the formal completion of the EMA's new policy on access to clinical trial data. The London-based regulatory agency disclosed late Wednesday that it was unable to agree on final wording for the new policy, which had been due to take effect Oct. 1. Read More

Improving traceability: Argentina takes global lead fighting fakes

BOGOTA, Colombia – A relatively young system to trace pharmaceutical products from manufacturer to patient has put Argentina at the forefront of the global fight against fake drugs. Read More

Close-up view of malaria proteins could yield new targets

LONDON – An eight-year study that involved sifting the genome of the malaria parasite has delivered a list of proteins that the parasite cannot do without – as well as determining at what point in the parasite's life cycle each of the proteins is expressed. Read More

Biocom aims to bridge San Diego cluster, global biotech industry

A report from real estate firm Jones Lang LaSalle last year listed San Diego as the number two biotech cluster in the U.S. Like any list, that ranking is debatable. Read More

Financings

Ocera Therapeutics Inc., of Palo Alto, Calif., priced an underwritten public offering of 4.2 million common shares at $6 apiece for gross proceeds of $25.2 million. Read More

Other news to note

Beike Biotechnology Co. Ltd., of Shenzhen, China, said following the recent Chinese Food and Drug Administration acceptance of its investigational new drug application seeking use of human umbilical cord-derived mesenchymal stem cells to treat lupus, the company anticipates approval to move ahead with the treatment by the end of this year. Read More

Stock movers

Read More

In the clinic

Transtech Pharma LLC, of High Point, N.C., said it reached an agreement with the FDA's Division of Neurology Products, under a special protocol assessment process, on the design of a single phase III trial of TTP448 for the treatment of patients with mild Alzheimer's disease. Read More

Pharma: Other news to note

Roche AG, of Basel, Switzerland, said its member firm, Ventana Medical Systems Inc., entered an agreement with Merck KGaA, of Darmstadt, Germany, to collaborate with Merck's biopharmaceutical division on the development and commercialization of a companion diagnostic for an undisclosed target using Ventana's diagnostic assays. Read More

Pharma: In the clinic

Novartis AG, of Basel, Switzerland, said the New England Journal of Medicine published the results from two pivotal phase III studies evaluating the interleukin-17A (IL-17A) inhibitor secukinumab, which met all primary and key secondary endpoints in the ERASURE and FIXTURE studies, including Psoriasis Area and Severity Index 75 and 90 and Investigator's Global Assessment modified 2011 0/1 responses. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 5, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 5, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 3, 2025
  • Woman holding neck

    Merus combo trounces Keytruda in head-and-neck phase II

    BioWorld
    Investor hopes rose sharply for Merus NV’s phase III trials – data should roll out next year – with bispecific antibody petosemtamab after mid-stage results...
  • Biotech deal illustration

    City hits the town with $1B-plus deal with Biogen

    BioWorld
    A development deal with Biogen Inc. could eventually bring City Therapeutics Inc. about $1 billion in milestone payments. It’s a step in the direction the company...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe